In a recent move, the government has taken a decisive step to ban 14 fixed-dose combination drugs, including the widely used medication Nimesulide. Citing potential risks to public health, regulatory authorities have undertaken a comprehensive evaluation of these drug combinations. Nimesulide, known for its effectiveness in pain relief and reducing inflammation, has faced concerns regarding its impact on liver health. By implementing this ban, the government aims to prioritize the well-being and safety of the population. This decision underscores the government’s commitment to stringent regulatory measures and their proactive approach to safeguarding public health. For additional information, please consult the linked article.